A nanovehicle developed for treating deep-seated bacteria using low-dose X-ray
Chien-Lin Pan1, Ming-Hong Chen2, Fu-I Tung3
1Department of Biomedical Engineering, National Yang-Ming University, Taipei, Taiwan, ROC.
Acta Biomaterialia
|October 8, 2016
Summary
A novel nanovehicle using vancomycin-conjugated graphene oxide quantum dots and Protoporphyrin IX (Van-GQDs/PpIX) offers a bacteria-specific, low-dose X-ray-activated treatment for infections. This approach effectively kills bacteria without harming healthy cells and shows no resistance development.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Antimicrobial Research
Background:
- Antibiotic resistance and limitations of high-dose antibiotics necessitate novel treatment strategies for bacterial infections.
- Existing non-antibiotic approaches like photocatalysis and photodynamic therapy face challenges with bacterial specificity and limited light penetration depth.
- Deep-seated infections, such as osteomyelitis, require treatments that can penetrate tissues effectively without causing collateral damage.
Purpose of the Study:
- To develop a bacteria-specific nanovehicle for targeted bacterial killing using low-dose X-ray activation.
- To overcome the limitations of specificity and penetration depth associated with current non-antibiotic therapies.
- To create a novel therapeutic approach for deep-seated bacterial infections as an alternative to antibiotics.
Main Methods:
- Conjugation of vancomycin (Van) to graphene oxide quantum dots (GQDs) and assembly with Protoporphyrin IX (PpIX) to form Van-GQDs/PpIX complex.
- Utilizing low-dose X-ray irradiation to activate the Van-GQDs/PpIX complex for targeted reactive oxygen species (ROS) generation.
- Evaluating the specificity, efficacy, and resistance development of the Van-GQDs/PpIX complex against Escherichia coli in vitro.
Main Results:
- The Van-GQDs/PpIX complex specifically attached to Escherichia coli, enhancing intracellular ROS generation upon X-ray activation.
- The nanovehicle effectively damaged the bacterial cell wall and enhanced X-ray-induced PpIX activation, leading to bactericidal effects.
- No bacterial resistance to the Van-GQDs/PpIX approach was observed after multiple administrations over a week, and normal cells remained undamaged.
Conclusions:
- The bacteria-specific, X-ray-activated Van-GQDs/PpIX nanovehicle presents a promising alternative to conventional antibiotics for treating serious bacterial infections.
- This approach overcomes key limitations of existing non-antibiotic strategies, offering enhanced specificity and deep tissue penetration.
- The developed nanovehicle holds potential for treating deep-seated infections like osteomyelitis and peritonitis, reducing the need for amputation.
